

Table 1. Summary of Natural History Study Mechanistic Samples for Participants over Baseline & Follow-up (Incomplete Collection/Visit Hx Permissible*). Subjects that Develop T1D at some point during P2 or P3 are Excluded.
 P2 (n=983); P3:6m (n=446); P3:12m (n=297); P3:18m (n=175) P3:24m (n=99); P3:30m (n=51); P3:36m (n=13)

Collection Phase*	Sample Type**	No. Subjects (% Row Total): <25%	No. Subjects (% Row Total): 25-50%	No. Subjects (% Row Total): >=25%	No. Subjects (% Row Total): >=50%	Risk Missing or TBD	Total No. Subjects Submitting Sample
Baseline	DNA	239 (40.4)	33 (5.6)	43 (7.3)	217 (36.7)	60 (10.1)	592
	HLA	397 (41.4)	35 (3.7)	85 (8.9)	319 (33.3)	122 (12.7)	958
	RNA	192 (41.5)	25 (5.4)	35 (7.6)	159 (34.3)	52 (11.2)	463
	PLASMA	191 (42.4)	24 (5.3)	33 (7.3)	155 (34.4)	47 (10.4)	450
	SERUM	191 (42.3)	25 (5.5)	35 (7.7)	154 (34.1)	47 (10.4)	452
	PBMC	188 (41.7)	24 (5.3)	35 (7.8)	155 (34.4)	49 (10.9)	451
Follow-up (6m)	RNA	98 (41.9)	18 (7.7)	18 (7.7)	89 (38.0)	11 (4.7)	234
	PLASMA	95 (41.3)	18 (7.8)	18 (7.8)	88 (38.3)	11 (4.8)	230
	SERUM	97 (41.6)	18 (7.7)	18 (7.7)	88 (37.8)	12 (5.2)	233
	PBMC	95 (41.3)	18 (7.8)	18 (7.8)	88 (38.3)	11 (4.8)	230
Follow-up (12m)	RNA	66 (38.2)	17 (9.8)	11 (6.4)	67 (38.7)	12 (6.9)	173
	PLASMA	66 (38.8)	17 (10.0)	11 (6.5)	64 (37.6)	12 (7.1)	170
	SERUM	65 (38.5)	17 (10.1)	10 (5.9)	65 (38.5)	12 (7.1)	169
	PBMC	67 (38.7)	17 (9.8)	11 (6.4)	66 (38.2)	12 (6.9)	173
Follow-up (18m)	RNA	50 (39.1)	15 (11.7)	1 (0.8)	57 (44.5)	5 (3.9)	128
	PLASMA	50 (39.7)	15 (11.9)	1 (0.8)	55 (43.7)	5 (4.0)	126
	SERUM	49 (39.2)	15 (12.0)	1 (0.8)	55 (44.0)	5 (4.0)	125
	PBMC	50 (39.1)	15 (11.7)	1 (0.8)	57 (44.5)	5 (3.9)	128
Follow-up (24m)	RNA	29 (39.2)	8 (10.8)	1 (1.4)	33 (44.6)	3 (4.1)	74
	PLASMA	29 (39.2)	8 (10.8)	1 (1.4)	33 (44.6)	3 (4.1)	74
	SERUM	29 (39.2)	8 (10.8)	1 (1.4)	33 (44.6)	3 (4.1)	74
	PBMC	29 (39.2)	8 (10.8)	1 (1.4)	33 (44.6)	3 (4.1)	74
Follow-up (30m)	RNA	16 (35.6)	4 (8.9)	1 (2.2)	21 (46.7)	3 (6.7)	45
	PLASMA	17 (37.0)	4 (8.7)	1 (2.2)	21 (45.7)	3 (6.5)	46
	SERUM	17 (37.0)	4 (8.7)	1 (2.2)	21 (45.7)	3 (6.5)	46
	PBMC	17 (37.0)	4 (8.7)	1 (2.2)	21 (45.7)	3 (6.5)	46
Follow-up (36m)	RNA	4 (33.3)	1 (8.3)	. (.)	3 (25.0)	4 (33.3)	12
	PLASMA	4 (33.3)	1 (8.3)	. (.)	3 (25.0)	4 (33.3)	12
	SERUM	4 (33.3)	1 (8.3)	. (.)	3 (25.0)	4 (33.3)	12
	PBMC	4 (33.3)	1 (8.3)	. (.)	3 (25.0)	4 (33.3)	12

* A subject enumerated in any Phase 3 visit is required to have had a Baseline (Phase 2) visit, although a subject doesn't necessarily need to have completed all prior P3 visits for inclusion in their latest P3 visit.

** All DNA samples collected -- across all visits herein (Baseline and any Phase 3 follow-up) -- are presented at Baseline. Note that a subject should have only provided one DNA sample, although it is possible multiple were provided.